Rallybio price target lowered to $13 from $14 at Wedbush

Wedbush lowered the firm’s price target on Rallybio to $13 from $14 and keeps an Outperform rating on the shares. The firm notes Rallybio announced a reprioritization of pipeline efforts in combination with a 45% workforce reduction. The moves extend cash runway into mid-2026 and keep the company predominantly focused on the RLYB212 in fetal and neonatal alloimmune thrombocytopenia.